Targeted radiotherapy for neuroblastoma

Background
Biologically targeted radiotherapy is an established treatment for thyrotoxicosis and thyroid cancer. The principle is to take advantage of the ability of the thyroid and, to a lesser degree, differentiated thyroid carcinoma to concentrate and retain iodide. In this situation the radiouclide \(^{131}\text{I}\) in ionic form is a natural substrate for targeting thyroid tissue, thus acting both as the vector, or ‘missile’, and the ‘warhead’. The success of this form of radiotherapy in metastatic papillary and follicular thyroid carcinoma is due to the specificity of targeting and the resulting concentration and retention of \(^{131}\text{I}\) in cells of thyroid origin, after the ablation of residual normal thyroid tissue, being sufficient to result in tumour eradication. Unfortunately the thyroid is unique and targeted radiodine treatment for other tumours requires specific vectors to carry the ‘warhead’. With the development of monoclonal antibodies in 1975 it was hoped that Erlich’s concept of an immunological magic bullet would quickly be realised, but more than 20 years later the applications of targeted monoclonal antibody treatment are distinctly limited in clinical oncology. There are several reasons for this failure of monoclonal antibodies to produce results: firstly, antigen expression on tumour cells is variable and tumour antigens are often expressed to some degree on normal cells, so the specificity is poor. Furthermore there is often poor penetration of large immune globulin molecules into tumours, a problem which has not been overcome to any significant degree by employing smaller molecular weight fragments. Furthermore murine monoclonal antibodies are themselves immunogenic and this precludes repeated administration. Despite these limitations, there have been attempts to employ targeted monoclonals in the treatment of neuroblastoma and regional targeting of leukaemia within the cerebrospinal fluid has produced responses.

The search has continued for low molecular weight compounds, which utilise metabolic pathways with high tumour specificity. Currently one of the most promising compounds is metaiodobenzylguanidine (mIBG) which exploits the active uptake pathway for noradrenaline expressed in sympathetically innervated tissues and in tumours of neural crest origin. Radioiodinated adrenergic blocking agents were originally developed as adrenomedullary imaging agents and the first human studies were described in adults with pheochromocytoma and soon after in children with neuroblastoma. Laboratory studies have elucidated the mechanism of uptake of mIBG in neural crest tumours, while clinical studies have exploited the high affinity of \(^{131}\text{I}\)-mIBG for neuroblastoma in particular and targeted treatment is now moving into front line investigational protocols in Europe.

Radiotherapy

Biologically targeted radiotherapy is an established treatment for thyrotoxicosis and thyroid cancer. The principle is to take advantage of the ability of the thyroid and, to a lesser degree, differentiated thyroid carcinoma to concentrate and retain iodide. In this situation the radiouclide \(^{131}\text{I}\) in ionic form is a natural substrate for targeting thyroid tissue, thus acting both as the vector, or ‘missile’, and the ‘warhead’. The success of this form of radiotherapy in metastatic papillary and follicular thyroid carcinoma is due to the specificity of targeting and the resulting concentration and retention of \(^{131}\text{I}\) in cells of thyroid origin, after the ablation of residual normal thyroid tissue, being sufficient to result in tumour eradication. Unfortunately the thyroid is unique and targeted radiodine treatment for other tumours requires specific vectors to carry the ‘warhead’. With the development of monoclonal antibodies in 1975 it was hoped that Erlich’s concept of an immunological magic bullet would quickly be realised, but more than 20 years later the applications of targeted monoclonal antibody treatment are distinctly limited in clinical oncology. There are several reasons for this failure of monoclonal antibodies to produce results: firstly, antigen expression on tumour cells is variable and tumour antigens are often expressed to some degree on normal cells, so the specificity is poor. Furthermore there is often poor penetration of large immune globulin molecules into tumours, a problem which has not been overcome to any significant degree by employing smaller molecular weight fragments. Furthermore murine monoclonal antibodies are themselves immunogenic and this precludes repeated administration. Despite these limitations, there have been attempts to employ targeted monoclonals in the treatment of neuroblastoma and regional targeting of leukaemia within the cerebrospinal fluid has produced responses.

The search has continued for low molecular weight compounds, which utilise metabolic pathways with high tumour specificity. Currently one of the most promising compounds is metaiodobenzylguanidine (mIBG) which exploits the active uptake pathway for noradrenaline expressed in sympathetically innervated tissues and in tumours of neural crest origin. Radioiodinated adrenergic blocking agents were originally developed as adrenomedullary imaging agents and the first human studies were described in adults with pheochromocytoma and soon after in children with neuroblastoma. Laboratory studies have elucidated the mechanism of uptake of mIBG in neural crest tumours, while clinical studies have exploited the high affinity of \(^{131}\text{I}\)-mIBG for neuroblastoma in particular and targeted treatment is now moving into front line investigational protocols in Europe.

The distribution of mIBG in surgically excised human neuroblastoma tumours has been studied 24–48 hours after intravenous administration of \(^{123}\text{I}\)-mIBG: an inhomogeneous distribution within individual tumours was found, with the most avid uptake in areas of viable undifferentiated neuroblasts. A study of the intracellular distribution of mIBG in human SK-N-SH neuroblastoma cell lines, xenografted into nude mice, by means of microautoradiography and secondary ion mass spectrometry microscopy, confirmed highly non-uniform distribution and, at an intracellular level, most of the radiopharmaceutical accumulated in the cytosol and perinuclear areas. These observations are of importance in selecting the most appropriate radionuclide emitter(s) for use in targeted treatment.

Radiobiology

Neuroblastoma is one of the most radiosensitive of all human tumours and external beam radiotherapy is employed with good benefit in the local control of disease, but the dose constraints of total body irradiation (TBI) preclude effective systemic radiotherapy. Even the combination of TBI with high dose chemotherapy and autologous bone marrow rescue has failed to show any benefit over high dose chemotherapy alone. If higher radiation doses could be delivered to the tumour while sparing normal tissues, radiotherapy has curative potential in this disease.

The radiobiological considerations that determine the efficacy of radioiodinated mIBG in neuroblastoma have been the subject of study and there is no evidence to suggest that active transport induced cell death is generally assumed to result from lethal damage to the nucleus. As the cellular diameter of a neuroblast is 10–20 µm and as the particular emission
from $^{131}$I has a mean range of 800 μm, this will result in a ‘crossfire’ effect from adjacent cells that take up mIBG into cells that do not. This would be predicted to be advantageous in non-homogeneous tumours and, at the same time, potentially disadvantageous for example in the case of marrow infiltration where adjacent haematopoietic cells would be within range. $^{131}$I emits Auger electrons with a range of ~1 μm and would therefore not exert any ‘crossfire’ effect, but ideally should be taken into the nucleus to exert maximum effect. $^{123}$I mIBG has been used for therapy at the University of Michigan. An α emitting radionuclide would, in theory at least, be ideal. $^{211}$At-meta-
statastobenzylguanidine has been synthesised and has been shown to induce in vitro cytotoxicity much more efficiently than $^{123}$I-mIBG, however there are major logistical problems related to production and safety that will probably preclude this agent for in vivo human treatment.

Another important variable in mIBG treatment is the specific activity of the radiopharmaceutical. Commercially available $^{131}$I-mIBG is of relatively low specific activity, that is the ratio of cold to radiolabelled molecules is high, and the cold molecules will compete for binding sites resulting in suboptimal tumour concentrations. Methods now exist for synthesis of high specific activity (or no carrier added) $^{131}$I-mIBG. The high specific activity preparation is to be expected to enhance tumour uptake by a factor of around 10 as a result of improved target-to-background ratios, but large scale production is thought not to be commercially viable at the present time.

Mathematical modelling predicts that $^{131}$I-mIBG would be most effective in smaller micrometastases. The ideal size is predicted to contain ~10$^6$ cells, with a lower cell kill in micrometastases smaller or larger than this. A study of spheroids of the human neuroblastoma cell line SK-H-BE (2c) of 250 μm and 400 μm size incubated in $^{131}$I-mIBG has shown that the larger size spheroids had a greater vulnerability as predicted by the model. It may well be that targeted $^{131}$I-mIBG therapy can ‘fill the gap’ between chemotherapy, which is most effective in very small micrometastases, and external beam radiotherapy and surgery, which are more efficient in dealing with macroscopic tumours. These observations are also relevant to the sequencing of multimodal treatment and predict that targeted $^{131}$I-mIBG treatment should be employed earlier rather than later in relation to chemotherapy.

Clinical studies

Neuroblastoma remains the major therapeutic challenge in paediatric oncology and new treatment strategies are needed. Despite response rates of approximately 75% with modern dose intensive induction chemotherapy and high dose consolidation with stem cell rescue, no more than 25% of children over 1 year of age at diagnosis of metastatic neuroblastoma will be long term survivors.

By 1991 reports had documented more than 250 children with advanced neuroblastoma who had received $^{131}$I-mIBG treatment. All of these treatments had been given to patients with chemoresistant disease either after induction chemotherapy or at relapse. Although the indications for treatment, methods of administration and criteria for assessment of response were variable, three of these earlier studies will be singled out:

1. A phase II study from the Netherlands Cancer Institute reported on 53 patients with progressive or recurrent disease in whom conventional treatment had failed. Empirical therapeutic activities of 3.7–7.4 GBq were given and some received more than one treatment. The results showed complete responses in 7/53 patients (13%), partial responses (>50% reduction in tumour volume) in 23/53 (43%), and stable disease in a further 10 patients (19%).

2. The German Neuroblastoma Trial published results on 47 children who progressed or relapsed after treatment with standard chemotherapy. Patients received 1–6 courses of $^{131}$I-mIBG (mean total activity 14.4 GBq). The results showed that 9/47 patients (19%) achieved a complete or very good partial response, and a partial response was seen in a further 13 patients (28%).

3. The prospective United Kingdom Children’s Cancer Study Group (UKCCSG) phase I/II study, which was a dose finding and toxicity study of $^{131}$I-mIBG therapy in stage 4 patients with a poor response to chemotherapy, reported partial responses in 8/24 patients (33%).

These three studies demonstrate that mIBG has single agent efficacy comparable with that of the chemotherapy drugs presently employed in induction protocols.

An important single centre study of mIBG as first line treatment for high risk neuroblastoma was started in Amsterdam in 1991. An interim report describes the first 31 children with inoperable neuroblastoma treated with a minimum of two cycles of $^{131}$I-mIBG (7.4 GBq followed by 3.7 GBq). Thereafter, operability was assessed and, if the primary tumour was deemed resectable, further fractions of 3.7 GBq of $^{131}$I-mIBG were administered. Chemotherapy was reserved for those who failed to become operable after repeated $^{131}$I-mIBG treatments (7/31) and for those with residual disease after surgical resection of the primary tumour. Isolated depression of the platelet count was seen in only 11 patients, while two patients developed pancytopenia. Severe thrombocytopenia was not encountered despite extensive bone marrow infiltration in some of these patients. The treatment was extremely well tolerated with virtually no sickness, no hair loss, and a mean weight gain of 9.5% between diagnosis and surgery. Eighty one per cent responded at metastatic sites and 73% responded at the primary site. Only 8/31 had an inadequate response to $^{131}$I-mIBG treatment and went onto chemotherapy. At surgery 16/31 had a >95% resection and 3/31 a partial resection of their tumour.

Future strategies

The radiobiological considerations predict that the combination of mIBG and chemotherapy administered as initial treatment for neuroblastoma would be the optimum clinical strategy. At least in vitro, synergy can be demonstrated between external beam radiation treatment and platinum derivatives. Pretreatment with cisplatin might enhance mIBG uptake into neuroblasts. The feasibility of treating children with a mIBG/cisplatin combination has been reported in relapsed neuroblastoma, but the optimum sequence and dose in newly diagnosed patients has still to be determined.

The UKCCSG is engaged in a multicentre pilot phase I study in poor prognosis newly diagnosed patients. This is essentially a feasibility and dose finding study of mIBG administered as initial treatment five days before the standard OPEC/OJEC chemotherapy protocol. The aim is
to perform whole body dosimetry at the time of the diagnostic 131I-mIBG scan in order to calculate the activity of 131I-mIBG that will deliver the required whole body dose. The logistics of delivering targeted radiotherapy within two weeks of diagnosis in young children, who are systemically ill and need to be nursed in a radiation protected environment with limited parental contact for several days, are considerable but can be surmounted by having the radiation facility within the paediatric oncology ward. The principle is to employ the maximum tolerated dose of 131I-mIBG and the haematological and any other toxicity of a starting whole body dose of 1.5 Gy will be determined before dose escalation. The aim is to set up a national randomised trial in stage 4 neuroblastoma, possibly in collaboration with other European groups, to compare the remission rate induced by the current most effective chemotherapy with that of combined treatment.

Conclusions

Although it is more than 10 years since mIBG was first used to treat neuroblastoma, there is still some way to go before the therapy is optimised. There is considerable potential for this modality to improve the results of treatment of advanced stage neuroblastoma, but it is too soon to know which of the new strategies employing mIBG will be the most effective in achieving sustained remissions. It is clear that the short term toxicity is considerably less than that of current chemotherapy regimens, but there is a need to be vigilant for the possible long term toxicities of 131I-mIBG treatment and, although there are few long term survivors to date, there is already one report of late thyroid dysfunction. There is also a theoretical risk of radiation damage to the bladder wall, radiation induced secondary malignancy, and adrenal insufficiency consequent to high dose targeted radioiodine treatment.

SIMON MELLER

Children’s Department,
Royal Marsden NHS Trust,
Dorset Road, Sutton,
Surrey SM2 5PT

8 Sisson JC, Janssen M, Rengers M, Biren E, Kuiters F, Buitenhuis C. Pharmacokinetics and intracellular distribution of the tumor-targeted radiopharmaceuti